Disciplined Equity Management Inc. Invests $53,000 in Danaher Co. (NYSE:DHR)

Disciplined Equity Management Inc. purchased a new position in shares of Danaher Co. (NYSE:DHR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 227 shares of the conglomerate’s stock, valued at approximately $53,000.

Several other institutional investors have also made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in shares of Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after acquiring an additional 3,905,449 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Danaher by 6.5% in the third quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock valued at $2,030,327,000 after buying an additional 502,868 shares during the period. Northern Trust Corp boosted its position in shares of Danaher by 1.7% during the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after purchasing an additional 134,905 shares in the last quarter. Flossbach Von Storch AG grew its position in Danaher by 1.8% in the 4th quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock valued at $1,064,477,000 after purchasing an additional 82,672 shares during the period. Finally, Invesco Ltd. increased its position in shares of Danaher by 13.2% during the third quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock worth $1,009,880,000 after acquiring an additional 473,693 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on DHR. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price target for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Barclays increased their price objective on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Bank of America lifted their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $270.00.

Danaher Stock Down 1.1 %

Shares of DHR stock traded down $2.70 during midday trading on Wednesday, reaching $250.41. 3,064,441 shares of the stock were exchanged, compared to its average volume of 2,783,958. The firm has a market cap of $185.44 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 3.96 and a beta of 0.83. The company’s 50 day moving average is $249.00 and its two-hundred day moving average is $230.78. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.36 EPS. On average, equities research analysts predict that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a $0.27 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Wednesday, March 27th. Danaher’s payout ratio is presently 16.90%.

Insider Activity at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock valued at $8,265,802 over the last ninety days. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.